ZeroHarm Sciences Raises Rs 65 Cr ($7.15 M) in Series A Funding Round

Why It Matters

The capital injection accelerates ZeroHarm’s push into high‑growth markets and validates investor confidence in nano‑enhanced nutraceuticals, potentially reshaping efficacy standards in the sector.

Key Takeaways

• Raised Rs 65 crore Series A led by Kotak Life Sciences.
• Funds target brand building, US/UK/Middle East expansion.
• Nano‑formulation boosts bioavailability of plant‑based nutrients.
• Over 60 SKUs serve 300k+ customers across health categories.
• Controls supply chain via 10,000+ farmers, holds multiple patents.

Pulse Analysis

India’s nutraceutical sector is on a rapid growth trajectory, with domestic revenues projected to hit $18 billion by 2025 and the global market expected to surpass $720 billion by 2027. ZeroHarm Sciences, founded in 2020, differentiates itself by applying proprietary nano‑formulation to plant‑based ingredients, a method that enhances bioavailability and enables lower‑dose, controlled‑release supplements. By marrying Ayurvedic sourcing with cutting‑edge nanotechnology, the Hyderabad‑based firm claims measurable health outcomes, positioning its “Trust over Promise” platform as a potential benchmark for efficacy in a crowded market.

The recent Rs 65 crore Series A, led by Kotak Alternate Asset Managers and Alkemi Growth Capital, gives ZeroHarm the capital to accelerate brand building and pursue international roll‑outs in the United States, United Kingdom and the Middle East. The infusion will also fund scale‑up of research labs and manufacturing lines, leveraging a vertically integrated supply chain that sources raw material from over 10,000 farmers across Northeast India and the Himalayas. With more than 60 product SKUs and a customer base exceeding 300,000, the company is poised to capture a larger share of both domestic and export markets.

Investors are increasingly attracted to nutraceuticals that combine scientific validation with traditional wellness concepts, and ZeroHarm’s patent portfolio across turmeric, iron‑folic‑acid, carotenoid and synbiotic formulations reinforces its defensibility. As competitors such as Kapiva and HealthKart expand their digital footprints, ZeroHarm’s focus on nano‑enhanced efficacy could become a differentiator in retail and e‑commerce channels like Amazon and Flipkart. If the firm successfully translates its technology into consistent clinical outcomes, it may set new standards for product credibility, prompting further capital inflows and accelerating consolidation in the Indian health‑supplement space.

Deal Summary

ZeroHarm Sciences, a nano‑formulated plant‑based nutraceutical brand, raised Rs 65 crore ($7.15 million) in a Series A round. Investors Kotak Alternate Asset Managers Limited (via its Kotak Life Sciences Fund I) and Alkemi Growth Capital contributed Rs 40 crore and Rs 25 crore respectively. The capital will support brand building, international expansion, and scaling of research and manufacturing.